Journal of the Formosan Medical Association
Volume 109, Issue 2 , Pages 94-105 , February 2010

HIV-1 gp41 Fusion Intermediate: A Target for HIV Therapeutics

  • Chungen Pan

      Affiliations

    • Laboratory of Viral Immunology, Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY, USA
    • College of Life Sciences, Peking University, Beijing, Guangzhou, China
    • ,
  • Shuwen Liu

      Affiliations

    • School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, China
    • ,
  • Shibo Jiang

      Affiliations

    • Laboratory of Viral Immunology, Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY, USA
    • School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, China
    • Corresponding Author InformationCorrespondence to: Dr Shibo Jiang, Laboratory of Viral Immunology, Lindsley F. Kimball Research Institute, New York Blood Center, 310 East 67th Street, New York, NY 10065, USA

Received 24 September 2009 ,Revised 25 September 2009 ,Accepted 25 September 2009.

References 

  1. Huang LM , Jeang KT . HIV-1 at age 25: some thoughts for Taiwan and China . J Formos Med Assoc . 2008;107:907–908
  2. Barre-Sinoussi F , Chermann JC , Rey F , et al.   Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS) . Science . 1983;220:868–871
  3. Gallo RC , Salahuddin SZ , Popovic M , et al.   Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS . Science . 1984;224:500–503
  4. FDA-approved antiretrovial (ARV) drugs . Available at http://www.hivandhepatitis.com/hiv_and_aids/hiv_treat.html [Date accessed: September 14, 2009]
  5. De Clercq E . Antiviral drugs in current clinical use . J Clin Virol . 2004;30:115–133
  6. Johnson VA , Brun-Vézinet F , Clotet B , et al.   Drug resistance mutations in HIV-1 . Top HIV Med . 2003;11:215–221
  7. Richman DD , Morton SC , Wrin T , et al.   The prevalence of antiretroviral drug resistance in the United States . AIDS . 2004;18:1393–1401
  8. Carr A , Cooper DA . Adverse effects of antiretroviral therapy . Lancet . 2000;356:1423–1430
  9. Chan DC , Chutkowski CT , Kim PS . Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target . Proc Natl Acad Sci USA . 1998;95:15613–15617
  10. Jiang S , Zhao Q , Debnath AK . Peptide and non-peptide HIV fusion inhibitors . Curr Pharm Des . 2002;8:563–580
  11. Liu S , Lu H , Niu J , et al.   Different from the HIV fusion inhibitor C34, the anti-HIV drug Fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120 . J Biol Chem . 2005;280:11259–11273
  12. Liu S , Jing W , Cheung B , et al.   HIV gp41 C-terminal hep-tad repeat contains multifunctional domains: relation to mechanisms of action of anti-HIV peptides . J Biol Chem . 2007;282:9612–9620
  13. Qi Z , Shi W , Xue N , et al.   Rationally designed anti-HIV peptides containing multifunctional domains as molecule probes for studying the mechanisms of action of the first and second generation HIV fusion inhibitors . J Biol Chem . 2008;283:30376–30384
  14. Lu M , Blacklow SC , Kim PS . A trimeric structural domain of the HIV-1 transmembrane glycoprotein . Nat Struct Biol . 1995;2:1075–1082
  15. Ji H , Shu W , Burling FT , et al.   Inhibition of HIV-1 infectivity by the gp41 core: role of a conserved hydrophobic cavity in membrane fusion . J Virol . 1999;73:8578–8586
  16. Dwyer JJ , Hasan A , Wilson KL , et al.   The hydrophobic pocket contributes to the structural stability of the N-terminal coiled coil of HIV gp41 but is not required for six-helix bundle formation . Biochemistry . 2003;42:4945–4953
  17. Chan DC , Fass D , Berger JM , et al.   Core structure of gp41 from the HIV envelope glycoprotein . Cell . 1997;89:263–273
  18. Weissenhorn W , Dessen A , Harrison SC , et al.   Atomic Structure of the Ectodomain from HIV-1 gp41 . Nature . 1997;387:426–428
  19. Chan DC , Kim PS . HIV entry and its inhibition . Cell . 1998;93:681–684
  20. Jiang S , Siddiqui P , Liu S . Blocking viral entry: a complementary strategy for HIV therapy . Drug Discovery Today: Therapeutic Strategies . 2004;1:497–503
  21. Liu S , Wu S , Jiang S . HIV entry inhibitors targeting gp41: from polypeptides to small-molecule compounds . Curr Pharm Design . 2007;13:143–162
  22. Jiang S , Lin K , Strick N , et al.   HIV-1 inhibition by a peptide . Nature . 1993;365:113
  23. Jiang S , Lin K , Strick N , et al.   Inhibition of HIV-1 infection by a fusion domain binding peptide from HIV-1 envelope glycoprotein gp41 . Biochem Biophys Res Commun . 1993;195:533–538
  24. Wild CT , Shugars DC , Greenwell TK , et al.   Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection . Proc Natl Acad Sci USA . 1994;91:9770–9774
  25. Lu M , Kim PS . A trimeric structural subdomain of the HIV-1 transmembrane glycoprotein . J Biomol Struct Dyn . 1997;15:465–471
  26. Lu M , Ji H , Shen S . Subdomain folding and biological activity of the core structure from human immunodeficiency virus type 1 gp41: implications for viral membrane fusion . J Virol . 1999;73:4433–4438
  27. Tan K , Liu J , Wang J , et al.   Atomic structure of a thermostable subdomain of HIV-1 gp41 . Proc Natl Acad Sci USA . 1997;94:12303–12308
  28. Kliger Y , Gallo SA , Peisajovich SG , et al.   Mode of action of an antiviral peptide from HIV-1. Inhibition at a post-lipid mixing stage . J Biol Chem . 2001;276:1391–1397
  29. Peisajovich SG , Gallo SA , Blumenthal R , et al.   C-terminal octylation rescues an inactive T20 mutant: implications for the mechanism of HIV/SIV-induced membrane fusion . J Biol Chem . 2003;278:21012–21017
  30. Kilby JM , Eron JJ . Novel therapies based on mechanisms of HIV-1 cell entry . N Engl J Med . 2003;348:2228–2238
  31. Wei X , Decker JM , Liu H , et al.   Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy . Antimicrob Agents Chemother . 2002;46:1896–1905
  32. Xu L , Hué S , Taylor S , et al.   Minimal variation in T-20 binding domain of different HIV-1 subtypes from antiretroviralnaive and -experienced patients . AIDS . 2002;16:1684–1686
  33. Lu J , Deeks SG , HOh R , et al.   Rapid emergence of enfuvirtide resistance in HIV-1-infected patients: results of a clonal analysis . J Acquir Immune Defic Syndr . 2006;43:6–14
  34. Sista PR , Melby T , Davison D , et al.   Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and on-treatment HIV-1 isolates . AIDS . 2004;18:1787–1794
  35. Kilby JM , Lalezari JP , Eron JJ , et al.   The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults . AIDS Res Hum Retroviruses . 2002;18:685–693
  36. Chinnadurai R , Rajan D , Munch J , et al.   Human immunodeficiency virus type 1 variants resistant to first- and secondversion fusion inhibitors and cytopathic in ex vivo human lymphoid tissue . J Virol . 2007;81:6563–6572
  37. Eron JJ , Gulick RM , Bartiett JA , et al.   Short-term safety and antiretroviral activity of T-1249, a second-generation fusion inhibitor of HIV . J Infect Dis . 2004;189:1075–1083
  38. Menzo S , Castagna A , Monachetti A , et al.   Genotype and phenotype patterns of human immunodeficiency virus type 1 resistance to enfuvirtide during long-term treatment . Antimicrob Agents Chemother . 2004;48:3253–3259
  39. Lalezari JP , Bellos NC , Sathasivam K , et al.   T-1249 retains potent antiretroviral activity in patients who had experienced virological failure while on an enfuvirtide-containing treatment regimen . J Infect Dis . 2005;191:1155–1163
  40. Melby T , Demasi R , Cammack N , et al.   Evolution of Genotypic and Phenotypic Resistance during Chronic Treatment with the Fusion Inhibitor T-1249 . AIDS Res Hum retroviruses . 2007;23:1366–1373
  41. Delmedico M, Bray B, Cammack N, et al. Next generation HIV peptide fusion inhibitor candidates achieve potent, durable suppression of virus replication in vitro and improved pharmacokinetic properties. In: 13th Conference on Retroviruses and Opportunistic Infections, 2006;5–8 [Abstract].
  42. Dwyer JJ , Wilson KL , Davison DK , et al.   Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus . Proc Natl Acad Sci USA . 2007;104:12772–12777
  43. He Y , Xiao Y , Song H , et al.   Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor . J Biol Chem . 2008;283:11126–11134
  44. FusoGen . Available at: http://www.fusogen.com [Date accessed: September 14, 2009]
  45. Wild C , Oas T , McDanal C , et al.   A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition . Proc Natl Acad Sci USA . 1992;89:10537–10541
  46. He Y , Cheng J , Li J , et al.   Identification of a critical motif for the HIV-1 gp41 core structure: implication for designing novel anti-HIV fusion inhibitors . J Virol . 2008;82:6349–6358
  47. He Y , Cheng J , Lu H , et al.   Potent HIV fusion inhibitors against Enfuvirtide-resistant HIV-1 strains . Proc Natl Acad Sci USA . 2008;105:16332–16337
  48. Otaka A , Nakamura M , Nameki D , et al.   Remodeling of gp41-C34 peptide leads to highly effective inhibitors of the fusion of HIV-1 with target cells . Angew Chem Int Ed Engl . 2002;41:2937–2940
  49. Sia SK , Carr PA , Cochran AG , et al.   Short constrained pep-tides that inhibit HIV-1 entry . Proc Natl Acad Sci USA . 2002;99:14664–14669
  50. Eckert DM , Malashkevich VN , Kim PS . Crystal structure of GCN4-pIQI, a trimeric coiled coil with buried polar residues . J Mol Biol . 1998;284:859–865
  51. Eckert DM , Malashkevich VN , Hong LH , et al.   Inhibiting HIV-1 entry: discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket . Cell . 1999;99:103–115
  52. Welch BD , VanDemark AP , Heroux A , et al.   Potent D-pep-tide inhibitors of HIV-1 entry . Proc Natl Acad Sci USA . 2007;104:16828–16833
  53. Deng Y , Zheng Q , Ketas TJ , et al.   Protein design of a bacte-rially expressed HIV-1 gp41 fusion inhibitor . Biochemistry . 2007;46:4360–4369
  54. Veazey RS , Klasse PJ , Schader SM , et al.   Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion . Nature . 2005;438:99–102
  55. Ni L , Gao GF , Tien P . Rational design of highly potent HIV-1 fusion inhibitory proteins: implication for developing antiviral therapeutics . Biochem Biophys Res Commun . 2005;332:831–836
  56. Pang W , Wang RR , Yang LM , et al.   Recombinant protein of heptad-repeat HR212, a stable fusion inhibitor with potent anti-HIV action in vitro . Virology . 2008;377:80–87
  57. Louis JM , Nesheiwat I , Chang L , et al.   Covalent trimers of the internal N-terminal trimeric coiled-coil of gp41 and antibodies directed against them are potent inhibitors of HIV envelope-mediated cell fusion . J Biol Chem . 2003;278:20278–20285
  58. Root MJ , Kay MS , Kim PS . Protein design of an HIV-1 entry inhibitor . Science . 2001;291:884–888
  59. Root MJ , Hamer DH . Targeting therapeutics to an exposed and conserved binding element of the HIV-1 fusion protein . Proc Natl Acad Sci USA . 2003;100:5016–5021
  60. Munch J , Ständker L , Adermann K , et al.   Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide . Cell . 2007;129:263–275
  61. Jiang S , Lin K , Lu M . A conformation-specific monoclonal antibody reacting with fusion-active gp41 from the HIV-1 envelope glycoprotein . J Virol . 1998;72:10213–10217
  62. Jiang S , Lin K , Zhang L , et al.   A screening assay for antiviral compounds targeted to the HIV-1 gp41 core structure using a conformation-specific monoclonal antibody . J Virol Methods . 1999;80:85–96
  63. Debnath AK , Radigan L , Jiang S . Structure-based identification of small molecule antiviral compounds targeted to the gp41 core structure of the human immunodecifiency virus type 1 . J Med Chem . 1999;42:3203–3209
  64. Jiang S , Debnath AK . A salt bridge between an N-terminal coiled coil of gp41 and an antiviral agent targeted to the gp41 core is important for anti-HIV-1 activity . Biochem Biophys Res Commun . 2000;270:153–157
  65. He Y , Liu S , Jing W , et al.   Conserved residue Lys574 in the cavity of HIV-1 gp41 coiled-coil domain is critical for six-helix bundle stability and virus entry . J Biol Chem . 2007;282:25631–25639
  66. He Y , Liu S , Li J , et al.   Conserved salt-bridge between the N- and C-terminal heptad repeat regions of HIV-1 gp41 core structure is critical for virus entry and inhibition . J Virol . 2008;82:11129–11139
  67. Jiang S , Lu H , Liu S , et al.   N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion . Antimicrob Agents Chemother . 2004;48:4349–4359
  68. Liu K , Lu H , Hou L , et al.   Design, synthesis, and biological evaluation of N-carboxyphenylpyrrole derivatives as potent HIV fusion inhibitors targeting gp41 . J Med Chem . 2008;51:7843–7854
  69. Katritzky AR , Tala SR , Lu H , et al.   Design, synthesis, and structure-activity relationship of a novel series of 2-Aryl 5-(4-oxo-3-phenethyl-2-thioxothiazolidin-ylidenemethyl)furans as HIV-1 entry inhibitors . J Med Chem . 2009;52:7631–7639
  70. Ferrer M , Kapoor TM , Strassmaier T , et al.   Selection of gp41-mediated HIV-1 cell entry inhibitors from biased combinatorial libraries of non-natural binding elements . Nat Struct Biol . 1999;6:953–960
  71. Ernst JT , Kutzki O , Debnath AK , et al.   Design of a protein surface antagonist based on alpha-helix mimicry: inhibition of gp41 assembly and viral fusion . Angew Chem Int Ed Engl . 2002;41:278–281
  72. Xu Y , Lu H , Kennedy JP , et al.   Evaluation of “credit card” libraries for inhibition of HIV-1 gp41 fusogenic core formation . J Comb Chem . 2006;8:531–539
  73. Gochin M , Savage R , Hinckley S , et al.   A fluorescence assay for rapid detection of ligand binding affinity to HIV-1 gp41 . Biol Chem . 2006;387:477–483
  74. Cai L , Gochin M . A novel fluorescence intensity screening assay identifies new low molecular weight inhibitors of the gp41 coiled coil domain of HIV-1 . Antimicrob Agents Chemother . 2007;51:2388–2395
  75. Ho DD . Therapy of HIV infections: problems and prospects . Bull N Y Acad Med . 1996;73:37–45
  76. Nagashima KA , Thompson DA , Rosenfield  , et al.   Human immunodeficiency virus type 1 entry inhibitors PRO 542 and T-20 are potently synergistic in blocking virus-cell and cell-cell fusion . J Infect Dis . 2001;183:1121–1125
  77. Tremblay CL , Kollmann C , Giguel F , et al.   Strong in vitro synergy between the fusion inhibitor T-20 and the CXCR4 blocker AMD-3100 . J Acquir Immune Defic Syndr . 2000;25:99–102
  78. Tremblay CL , Giguel F , Kollmann C , et al.   Anti-human immunodeficiency virus interactions of SCH-C (SCH 351125), a CCR5 antagonist, with other antiretroviral agents in vitro . Antimicrob Agents Chemother . 2002;46:1336–1339
  79. Pan C , Lu H , Qi Z , et al.   Synergistic efficacy of combination of enfuvirtide and sifuvirtide, the first- and next-generation HIV-fusion inhibitors . AIDS . 2009;23:639–641
  80. Pan C , Cai L , Lu H , et al.   Combinations of the first and next generation HIV fusion inhibitors exhibit highly potent synergistic effect against enfuvirtide-sensitive and resistant HIV-1 strains . J Virol . 2009;83:7862–7872
  81. Rimsky LT , Shugars DC , Matthews TJ . Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides . J Virol . 1998;72:986–993
  82. Eggink D , Baldwin CE , Deng Y , et al.   Selection of T1249-resistant Human Immunodeficiency Virus type 1 variants . J Virol . 2008;82:6678–6688
  83. Greenberg ML , Cammack N . Resistance to enfuvirtide, the first HIV fusion inhibitor . J Antimicrob Chemother . 2004;54:333–340
  84. Labrosse B , Morand-Joubert L , Goubard A , et al.   Role of the envelope genetic context in the development of enfu-virtide resistance in human immunodeficiency virus type 1-infected patients . J Virol . 2006;80:8807–8819
  85. Matthews T , Salgo M , Greenberg M , et al.   Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes . Nat Rev Drug Discov . 2004;3:215–225
  86. Mink M , Mosier SM , Janumpalli S , et al.   Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro . J Virol . 2005;79:12447–12454
  87. Ray N , Harrison JE , Blackbum LA , et al.   Clinical resistance to enfuvirtide does not affect susceptibility of human immunodeficiency virus type 1 to other classes of entry inhibitors . J Virol . 2007;81:3240–3250
  88. Ray N , Blackburn LA , Doms RW . HR-2 mutations in human immunodeficiency virus type 1 gp41 restore fusion kinetics delayed by HR-1 mutations that cause clinical resistance to enfuvirtide . J Virol . 2009;83:2989–2995
  89. Trivedi VD , Cheng SF , Wu CW , et al.   The LLSGIV stretch of the N-terminal region of HIV-1 gp41 is critical for binding to a model peptide, T20 . Protein Eng . 2003;16:311–317

PII: S0929-6646(10)60029-0

doi: 10.1016/S0929-6646(10)60029-0

Journal of the Formosan Medical Association
Volume 109, Issue 2 , Pages 94-105 , February 2010

Article Tools